GlobalData on MSN1 天
Lineage begins study of OPC1 delivering device for spinal cord injury treatment
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
美股内部交易 | Lineage Cell于2月12日披露2笔公司内部人交易情况
2025年2月12日， Lineage Cell（LCTX）披露2笔公司内部人交易情况。董事Culley Brian M于2025年2月11日卖出1.25万股。 【公司资料】 Lineage Cell Therapeutics, Inc.于1990年在加利福尼亚州成立。该公司是一家临床阶段的生物技术公司，开发新型同种异体或“现成的”细胞疗法，以满足未满足的医疗需求。公司项目基于公司专有的基于细胞的 ...
Pharmabiz15 小时
Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury
Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...
Lineage Cell Therapeutics initiates study of OPC1 for spinal injury
Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...
Business Wire2 天
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...
The Secret to Healthy Aging? Scientists Uncover the Power of Selenoproteins
A research team from Osaka University investigates the impact of antioxidant enzymes on specific cell types and their role in ...
Lineage Cell Therapeutics’ (LCTX) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a ...
Broadwood Partners收购Lineage Cell Therapeutics价值600万美元股份
Broadwood Partners, L.P.作为Lineage Cell Therapeutics, Inc. (NYSE: LCTX )的重要股东，已收购了该公司大量普通股。这次收购价值600万美元，涉及以每股0.76美元的价格购买7,894,737股普通股。该交易是2024年11月19日签订的证券购买协议的一部分，并于2025年1月27日在获得股东批准后完成。根据 InvestingPro ...
Promising Advancements in Cell Therapy: Lineage Cell Therapeutics Receives Buy Rating from ...
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated price ...
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that ...
Nasdaq13 天
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics
Lineage Cell Therapeutics (AMEX:LCTX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a ...
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a research note released on Friday,Benzinga reports. HC Wainwright currently has a ...